Tori Spelling says she lost about 40 pounds on Mounjaro after her fifth pregnancy

Tori Spelling says she used Mounjaro, the type 2 diabetes drug made with tirzepatide, to lose weight after her fifth pregnancy, and that she dropped about 40 pounds on it ^[1][2].

Spelling, best known for playing Donna Martin on "Beverly Hills, 90210," described the treatment on her podcast "misSPELLING" ^[1][2]. TODAY.com places the disclosure in an April episode, while Women's Health says she shared it on a Tuesday ^[1][2]. "I did Mounjaro, and everyone admits it now," she said on the episode, adding, "It's a different time so I don't feel shamed saying that" ^[1].

Her fifth child, Beau, was born in March 2017, when she was 44 ^[1]. Before that pregnancy she said her weight had sat near 120 pounds her entire life; afterward it reached 160. "I couldn't lose the weight, and the doctor was like, 'Well, it's an age thing,'" she recalled ^[1][2]. Earlier pregnancies were easier for her to recover from, she said, and this time a protein-focused diet and intermittent fasting did not change the number on the scale ^[1][2].

Women's Health reports that her doctor recommended Mounjaro together with hormone therapy because she was approaching menopause. "She put me simultaneously with the hormones on Mounjaro," Spelling said ^[2]. She is no longer taking the drug. She said she has not been on it since the end of January and that she came off it because she had reached the weight she wanted ^[1].

The two outlets give different ages for Spelling: TODAY.com says she is 51, and Women's Health says 50 ^[1][2]. Neither account includes her dose, how many months she took the drug, whether insurance covered it, or how the hormone therapy was chosen or followed.

Spelling has spoken about body image pressure since her first pregnancies. She told People in 2009 that she felt watched after giving birth, saying that people would "take pictures and scrutinize" within a week or two ^[1]. That same year she told Us Weekly she had gained roughly 40 pounds with each of her first two pregnancies and needed diet and exercise to lose it ^[1].

Why it matters for patients

The brand name matters here. Mounjaro is the name for tirzepatide when it is prescribed to help control blood sugar in people with type 2 diabetes; the same active ingredient is FDA-approved for weight loss under the brand name Zepbound ^[2]. Two labels, one molecule, two approved uses. People reading coverage of celebrity weight loss, or comparing their own prescriptions to what a public figure describes, are often looking at the same drug under a different name ^[2].

Spelling's case also pairs the drug with doctor-prescribed hormone therapy during the approach to menopause ^[2]. Public reporting on this combination is thin. Her reports do not say whether the two treatments were studied together for her situation, how long the hormone therapy lasted, or whether either prescription has continued. How common this combination is for women in perimenopause has not been reported, and what it does to weight over the long term is not established in these accounts ^[1][2].

One person's experience does not show what is typical or what is safe for anyone else. Details that would help a patient compare their own care, such as dose, duration, side effects, coverage and lab monitoring, are not in either report ^[1][2]. What the trials and prescribing labels say about tirzepatide for diabetes and for weight loss is separate from a podcast conversation.

What happens next

Spelling said she is off Mounjaro and satisfied with her weight ^[1]. No further details about her treatment, and no medical follow-up, have been disclosed ^[1][2].